The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds. X is, identically or differently in each occurrence, CR or N, or two adjacent X stand for a group of the following formula (2), wherein the dashed bonds mark the bonding of said group in formula (1), with the stipulation that the compound of formula (1) contains one or two groups of formula (2); X.sup.1 is, identically or differently in each occurrence, CR or N; Y is, identically or differently in each occurrence, CR or N; Z.sup.1, Z.sup.2, Z.sup.3 are, identically or differently in each occurrence, O, S, N—Ar or CR.sub.2.

The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds. X is, identically or differently in each occurrence, CR or N, or two adjacent X stand for a group of the following formula (2), wherein the dashed bonds mark the bonding of said group in formula (1), with the stipulation that the compound of formula (1) contains one or two groups of formula (2); X.sup.1 is, identically or differently in each occurrence, CR or N; Y is, identically or differently in each occurrence, CR or N; Z.sup.1, Z.sup.2, Z.sup.3 are, identically or differently in each occurrence, O, S, N—Ar or CR.sub.2.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

##STR00001##

For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.

Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.

An organic light emitting element produced by using a light emitting composition that contains both a first compound having a PBHT value more than 0.730 and a second compound having ES1 lower than that of the first compound and AEsT less than 0.20 eV is excellent in durability. ES1 is the lowest excited singlet energy level, AEsT is the difference between the lowest excited singlet energy level and the lowest excited triplet energy level.

A substituted heteroaryl compound, and a composition and application thereof. The compound is a compound as represented by formula (I) or a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as represented by formula (I). A drug composition contains the compound. The compound and the drug composition can adjust activity of a JAK kinase, particularly activity of TYK2, and are used for preventing, handling, treating and relieving diseases or disorder mediated by the activity of the JAK kinase.

##STR00001##

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. ##STR00001## For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. ##STR00001## For Formula I compounds X, Y, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and R.sup.5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.